223 related articles for article (PubMed ID: 23233725)
21. Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.
McClelland EE; Casadevall A
Fungal Genet Biol; 2012 Mar; 49(3):227-34. PubMed ID: 22327012
[TBL] [Abstract][Full Text] [Related]
22. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
Pirofski LA; Casadevall A
Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968
[TBL] [Abstract][Full Text] [Related]
23. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody.
Syme RM; Bruno TF; Kozel TR; Mody CH
Infect Immun; 1999 Sep; 67(9):4620-7. PubMed ID: 10456908
[TBL] [Abstract][Full Text] [Related]
24. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
Pirofski LA
Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
[TBL] [Abstract][Full Text] [Related]
25. Capsular polysaccharides of Cryptococcus neoformans.
Bhattacharjee AK; Bennett JE; Glaudemans CP
Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
[TBL] [Abstract][Full Text] [Related]
26. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
[TBL] [Abstract][Full Text] [Related]
27. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity.
Vecchiarelli A; Casadevall A
Res Immunol; 1998; 149(4-5):321-33; discussion 500-3. PubMed ID: 9720950
[No Abstract] [Full Text] [Related]
28. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy.
Goldman DL; Casadevall A; Zuckier LS
J Med Vet Mycol; 1997; 35(4):271-8. PubMed ID: 9292424
[TBL] [Abstract][Full Text] [Related]
30. Binding of the wheat germ lectin to Cryptococcus neoformans chitooligomers affects multiple mechanisms required for fungal pathogenesis.
Fonseca FL; Guimarães AJ; Kmetzsch L; Dutra FF; Silva FD; Taborda CP; Araujo Gde S; Frases S; Staats CC; Bozza MT; Schrank A; Vainstein MH; Nimrichter L; Casadevall A; Rodrigues ML
Fungal Genet Biol; 2013 Nov; 60():64-73. PubMed ID: 23608320
[TBL] [Abstract][Full Text] [Related]
31. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.
Taborda CP; Casadevall A
J Immunol; 2001 Feb; 166(3):2100-7. PubMed ID: 11160261
[TBL] [Abstract][Full Text] [Related]
32. The elastic properties of the Cryptococcus neoformans capsule.
Frases S; Pontes B; Nimrichter L; Rodrigues ML; Viana NB; Casadevall A
Biophys J; 2009 Aug; 97(4):937-45. PubMed ID: 19686640
[TBL] [Abstract][Full Text] [Related]
33. Molecular architecture of the Cryptococcus neoformans capsule.
Gates MA; Thorkildson P; Kozel TR
Mol Microbiol; 2004 Apr; 52(1):13-24. PubMed ID: 15049807
[TBL] [Abstract][Full Text] [Related]
34. Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation.
Robertson EJ; Casadevall A
Appl Environ Microbiol; 2009 Apr; 75(8):2528-33. PubMed ID: 19251903
[TBL] [Abstract][Full Text] [Related]
35. The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding.
Zaragoza O; Telzak A; Bryan RA; Dadachova E; Casadevall A
Mol Microbiol; 2006 Jan; 59(1):67-83. PubMed ID: 16359319
[TBL] [Abstract][Full Text] [Related]
36. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
37. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
Feldmesser M; Kress Y; Casadevall A
J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
[TBL] [Abstract][Full Text] [Related]
38. Detection of circulating capsular polysaccharide antigen from Cryptococcus neoformans.
Swinne D; De Vroey C
J Clin Microbiol; 1992 Sep; 30(9):2521. PubMed ID: 1401033
[No Abstract] [Full Text] [Related]
39. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
Parra C; González JM; Castañeda E; Fiorentino S
Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
[TBL] [Abstract][Full Text] [Related]
40. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
